Clinical Research Directory
Browse clinical research sites, groups, and studies.
Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Sponsor: Bjorn H. Ebdrup
Summary
Antipsychotics affects the brain's dopamine system, and the drugs reduce delusions, hallucinations, and disorganized thinking, which are cardinal symptoms of psychotic disorders. However, negative symptoms e.g. anhedonia, avolition, and social withdrawal, as well as cognitive deficits, are not sufficiently treated. Memantine is used to treat Alzheimer's disease and affects the brain's glutamate system. AMEND is a 12-week, double-blind, placebo-controlled, randomized clinical trial (RCT) testing effects of add-on memantine to initial antipsychotic treatment in never-treated patients with first-episode psychosis. The main aim is to reduce negative symptoms. Secondary outcomes are cognition, psychotic symptoms, side effects. Glutamate levels in the brain will be measured before and after 12 weeks using an ultra-high field strength (7 Tesla) magnetic resonance scanner. AMEND will apply rational drug repurposing to optimize treatment of patients experiencing their first psychotic episode.
Official title: AMEND - Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
46
Start Date
2021-05-26
Completion Date
2026-12-31
Last Updated
2024-12-09
Healthy Volunteers
Yes
Interventions
Memantine
Add on treatment with memantine to aripiprazole.
Placebo
Placebo add on to aripiprazole
Locations (1)
Centre for Neuropsychiatric Schizophrenia Research, CNSR & Centre for Clinical Intervention & Neuropsychiatric Schizophrenia Research, CINS
Glostrup Municipality, Capitol Region, Denmark